Quris Closes Critical Drug Development Gaps With New Clinical Prediction AI Platform
BOSTON and TEL-AVIV, Israel, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Quris , an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today launched the first clinical prediction AI platform to predict which drug candidates will safely work in humans dramatically improving efficacy and cutting drug development costs.
- BOSTON and TEL-AVIV, Israel, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Quris , an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today launched the first clinical prediction AI platform to predict which drug candidates will safely work in humans dramatically improving efficacy and cutting drug development costs.
- The first Quris drug addresses Fragile X syndrome (FXS), the most common inherited cause of autism and intellectual disabilities worldwide.
- Quris is the first AI platform to predict which drug candidates will safely work in humans, filling a critical gap in clinical prediction.
- Revolutionizing the drug development process, the company is pioneering clinical trials on chips testing thousands of novel drug candidates on hundreds of miniaturized patients-on-a-chip.